Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 125Lymphoid 26Gastrointestinal 26Genitourinary 21CNS 21Other hematologic neoplasm 20Sarcoma 16Thoracic 14Dermatologic 11Myeloid 7Gynecologic 6Head & Neck 4Endocrine 4Classical hematology 4Other solid neoplasm 3Breast 3Tumor-Agnostic 2NET 2Other neoplasm 1

Conditions

Neoplasms 2Neoplasms, Second Primary 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Thalidomide × Tumor-Agnostic × Clear all
NCT03777930 2018-12-19

The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol

Shenzhen Fifth People's Hospital

Phase 4 Unknown
200 enrolled
Tumor-Agnostic

Neoplasms, Neoplasms, Second Primary

NCT00165451 2011-07-07

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
20 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡